Radiation exposure in interventional radiology and other medical imaging modalities has become a serious concern, driven by the growing number of efficacious diagnostic and image-guided minimally invasive procedures and appropriately increasing utilization. This concern has been underlined by a recent FDA initiative to reduce dose in medical imaging. Alleviating this problem is complex because of the many contributing factors, but we believe that one part of the solution is to build X-ray imaging equipment that acquires images at significantly lower dose. In this spirit, we propose in this SBIR Fast-Track application to build a low-dose fluoroscopic system with a large field of view as required for interventional radiology. We expect that the system will reduce entrance X- ray exposure and radiation dose to the patient by a factor of 4 and the occupational dose by at least a factor of 2 at equal image quality as compared to a conventional system. We, Triple Ring Technologies, have developed a scanning-beam digital X-ray (SBDX) system with a small field of view for cardiac interventions, scheduled for release in fall 2010. The system employs a novel imaging geometry with an extended, scanning-beam X-ray source with 9,000 focal spot positions, and a pixelated photon-counting detector. From each focal-spot position, an X-ray beam is cast through an X-ray collimator onto the detector. The final image, composed of up to 9,000 detector images, is reconstructed in real time. The SBDX system has shown a 4-fold dose reduction in adult patients. To achieve the extended FOV, we will use the existing SBDX system and replace the single detector with two laterally spaced detectors. Importantly, this will require a new X-ray collimator and we determined that construction of the new collimator is the highest development risk. We propose to retire this risk in Phase 1 of the SBIR Fast-Track grant. In Phase 2 of the grant, we will build the large FOV system and perform a comparative phantom study of our system against a conventional system to measure entrance exposure, patient and occupational dose savings. Finally, we will perform an observer study in porcine models to validate image quality in comparison to a conventional system. In conclusion, this grant application proposes to reduce the radiation risk in interventional radiology by building and testing a low-dose fluoroscopy system.

Public Health Relevance

Interventional radiology is an expanding field with over 4 million minimally invasive procedures performed every year in the US alone. Despite its success, IR has recently come under scrutiny because many of the procedures are performed under X-ray image guidance. There is strong evidence that the elevated dose exposures as found in IR are leading to a significantly increased risk of cancer, especially in young patients. In this grant application we propose to address this concern by building a low-dose fluoroscopic system with a large field-of-view as required for interventional radiology. Importantly, our system will use inverse geometry architecture with an extended X-ray source and two small detectors. We hypothesize that our system will offer a 4-fold reduction in patient dose and 2-fold reduction in occupational dose with equivalent image quality as compared to a conventional system.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
1R44RR031964-01
Application #
8058877
Study Section
Special Emphasis Panel (ZRG1-SBMI-T (10))
Program Officer
Liu, Christina
Project Start
2011-02-15
Project End
2013-01-31
Budget Start
2011-02-15
Budget End
2013-01-31
Support Year
1
Fiscal Year
2011
Total Cost
$208,672
Indirect Cost
Name
Triple Ring Technologies, Inc.
Department
Type
DUNS #
184609621
City
Newark
State
CA
Country
United States
Zip Code
94560
Cureton, Elizabeth L; Yau, Christina; Alvarado, Michael D et al. (2014) Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 21:2889-96